Compare Lumen Technologies Inc (LUMN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Novo Nordisk A/S — how do they compare? Lumen Technologies Inc trades at $6.28 (market cap $6.58B), while Novo Nordisk A/S trades at $46.45 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 31.6× Lumen Technologies Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| LUMN | NVO | |
|---|---|---|
Market Cap | $6.58B | $207.85B |
Sector | Media | Health |
52-Week High | $11.83 | $63.98 |
52-Week Low | $3.95 | $35.29 |
Enterprise Value | $18.20B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN stock trades at $6.375, down 3.99% today, amid a bearish technical signal and mixed earnings. The company reported a Q2 2026 loss of $0.07 per share, beating estimates, but revenue declined 9.3% year-over-year. Strategic revenues grew 14.1%, highlighting its digital transformation. CEO Kathleen Johnson purchased 100,000 shares on August 6, 2026, signaling insider confidence. Net cash flow was negative $886 million in 2025, though 2026 projections show improvement. The stock faces headwinds from high debt and legacy revenue declines.
LUMN offers a high-risk opportunity with a low P/S ratio of 0.54 and analyst consensus price target of $7.67, implying potential upside. However, persistent net losses, negative ROE of -78.94%, and $17.49 billion in long-term debt pose significant risks. Investors should weigh the digital growth potential against financial instability and cautious analyst sentiment, with 60.71% holding ratings.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
